Nuclear localization of Matrix metalloproteinases

Progress in Histochemistry and Cytochemistry

Volumn 47, Issue 1, 2012, Pages 27-58

  Mannello, Ferdinando ^a   Medda, Virginia ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

Activation; Apoptosis; Artery occlusion; Brain; Breast; Cancer; CCN2 TCGF gene; Chondrocyte; Collagenase; Connective; Cytosol; Degradome; Endothelial cell; Extracellular matrix; Fibroblast; Furin; Gelatinase; Hepatocellular carcinoma; Inflammation; Inhibition; Internalization; Ischemia; Liver; Lung; Matrilysin; Matrix metalloproteinase; Matrixin; Membrane type metalloproteinase; Metzincin; Myocyte; Neuron; Nuclear localization sequence; Nucleus; Oligodendrocyte; PARP; Reperfusion; Stem cell; Stroke; Stromelysin; Tissue inhibitors of metalloproteinase; Translocation; XRCC1

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 26; METALLOPROTEINASE; METZINCIN PROTEIN; NEUTROPHIL COLLAGENASE; PROTEINASE; STROMELYSIN; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

BRAIN TISSUE; BREAST EXAMINATION; CANCER INVASION; CELL COMPARTMENTALIZATION; CELL NUCLEUS; CELL TYPE; CONNECTIVE TISSUE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HEART; HUMAN; INTRACELLULAR TRANSPORT; LIVER EXAMINATION; LUNG EXAMINATION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TISSUE INJURY; TUMOR GROWTH;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL COMPARTMENTATION; CELL NUCLEUS; CYTOSOL; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASES; MICE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS;

EID: 84856234425     PISSN: 00796336     EISSN: 18732186     Source Type: Journal    
DOI: 10.1016/j.proghi.2011.12.002     Document Type: Review

References (154)

1. Agah A., Kyriakides T.R., Bornstein P. Proteolysis of cell-surface tissue transglutaminase by matrix metalloproteinase-2 contributes to the adhesive defect and matrix abnormalities in thrombospondin-2-null fibroblasts and mice. Am J Pathol 2005, 167:81-88.
2. Aggarwal B.B., Takada Y., Oommen O.V. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 2004, 13:1327-1338.
3. Agrawal S.M., Lau L., Yong V.W. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008, 19:42-51.
4. Aldonyte R., Brantly M., Block E., Patel J., Zhang J. Nuclear localization of active matrix metalloproteinase-2 in cigarette smoke-exposed apoptotic endothelial cells. Exp Lung Res 2009, 35:59-75.
5. Alenius G.M., Jonsson S., Wallberg J.S., Ny A., Rantapaa D.S. Matrix metalloproteinase 9 (MMP-9) in patients with psoriatic arthritis and rheumatoid arthritis. Clin Exp Rheumatol 2001, 19:760.
6. Amantea D., Corasaniti M.T., Mercuri N.B., Bernardi G., Bagetta G. Brain regional and cellular localization of gelatinase activity in rat that have undergone transient middle cerebral artery occlusion. Neuroscience 2008, 152:8-17.
7. Amantea D., Russo R., Gliozzi M., Fratto V., Berliocchi L., Bagetta G., Bernardi G., Corasaniti M.T. Early upregulation of matrix metalloproteinases following reperfusion triggers neuroinflammatory mediators in brain ischemia in rat. Int Rev Neurobiol 2007, 82:149-169.
8. Annabi B., Lachambre M., Bousquet-Gagnon N., Page M., Gingras D., Beliveau R. Localization of membrane-type 1 matrix metalloproteinase in caveolae membrane domains. Biochem J 2001, 353:547-553.
9. Arbelaez L.F., Bergmann U., Tuuttila A., Shanbhag V.P., Stigbrand T. Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2-macroglobulin. Arch Biochem Biophys 1997, 347:62-68.
10. Bahar-Shany K., Ravid A., Koren R. Upregulation of MMP-9 production by TNFalpha in keratinocytes and its attenuation by vitamin D. J Cell Physiol 2010, 222:729-737.
11. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727.
12. Baronas-Lowell D., Lauer-Fields J.L., Al-Ghoul M., Fields G.B. Proteolytic profiling of the extracellular matrix degradome. Methods Mol Biol 2007, 386:167-202.
13. Bertini I., Calderone V., Cosenza M., Fragai M., Lee Y.M., Luchinat C., Mangani S., Terni B., Turano P. Conformational variability of matrix metalloproteinases: beyond a single 3D structure. Proc Natl Acad Sci U S A 2005, 102:5334-5339.
14. Bode W. (2003) Structural basis of matrix metalloproteinase function. Biochem Soc Symp1-14.
15. Braundmeier A.G., Fazleabas A.T., Lessey B.A., Guo H., Toole B.P., Nowak R.A. Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium. J Clin Endocrinol Metab 2006, 91:2358-2365.
16. Bravo-Cordero J.J., Marrero-Diaz R., Megias D., Genis L., Garcia-Grande A., Garcia M.A., Arroyo A.G., Montoya M.C. MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J 2007, 26:1499-1510.
17. Cauwe B., Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010, 45:351-423.
18. Chakrabarti S., Patel K.D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 2005, 31:599-621.
19. Chang C.K., Hung W.C., Chang H.C. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med 2008, 12:2781-2789.
20. Chernov A.V., Sounni N.E., Remacle A.G., Strongin A.Y. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. J Biol Chem 2009, 284:12727-12734.
21. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.
22. Coker M.L., Doscher M.A., Thomas C.V., Galis Z.S., Spinale F.G. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999, 277:H777-H787.
23. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
24. Cuadrado E., Rosell A., Borrell-Pages M., Garcia-Bonilla L., Hernandez-Guillamon M., Ortega-Aznar A., Montaner J. Matrix metalloproteinase-13 is activated and is found in the nucleus of neural cells after cerebral ischemia. J Cereb Blood Flow Metab 2009, 29:398-410.
25. De S.P., Elmakky A., Farina A., Caramelli E., Seracchioli R., Mabrouk M., Mignemi G., Venturoli S., Villa G., Guerrini M., Manuzzi L., Montanari G., Valvassori L., Zucchini C. Matrix metalloproteinase-3 mRNA: a promising peripheral blood marker for diagnosis of endometriosis. Gynecol Obstet Invest 2011, 71:118-123.
26. Donnini S., Morbidelli L., Taraboletti G., Ziche M. ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci 2004, 74:2975-2985.
27. Dorman G., Cseh S., Hajdu I., Barna L., Konya D., Kupai K., Kovacs L., Ferdinandy P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010, 70:949-964.
28. Egeblad M., Littlepage L.E., Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 2005, 70:383-388.
29. Eguchi T., Kubota S., Kawata K., Mukudai Y., Uehara J., Ohgawara T., Ibaragi S., Sasaki A., Kuboki T., Takigawa M. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol 2008, 28:2391-2413.
30. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., Cummings M.D., Romanic A.M. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr D Biol Crystallogr 2002, 58:1182-1192.
31. Fanjul-Fernandez M., Folgueras A.R., Cabrera S., Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 2010, 1803:3-19.
32. Fingleton B. Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 2007, 13:333-346.
33. Fiotti N., Zivadinov R., Altamura N., Nasuelli D., Bratina A., Tommasi M.A., Bosco A., Locatelli L., Grop A., Cazzato G., Guarnieri G., Giansante C., Zorzon M. MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol 2004, 152:147-153.
34. Folgueras A.R., Pendas A.M., Sanchez L.M., Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004, 48:411-424.
35. Gasche Y., Copin J.C., Sugawara T., Fujimura M., Chan P.H. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001, 21:1393-1400.
36. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011, 278:16-27.
37. Gilabert-Estelles J., Estelles A., Gilabert J., Castello R., Espana F., Falco C., Romeu A., Chirivella M., Zorio E., Aznar J. Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum Reprod 2003, 18:1516-1522.
38. Golubkov V.S., Boyd S., Savinov A.Y., Chekanov A.V., Osterman A.L., Remacle A., Rozanov D.V., Doxsey S.J., Strongin A.Y. Membrane type-1 matrix metalloproteinase (MT1-MMP) exhibits an important intracellular cleavage function and causes chromosome instability. J Biol Chem 2005, 280:25079-25086.
39. Gomis-Ruth F.X. Catalytic domain architecture of metzincin metalloproteases. J Biol Chem 2009, 284:15353-15357.
40. Gottschall P.E., Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 1996, 3:69-75.
41. Gross J., Nagai Y. Specific degradation of the collagen molecule by tadpole collagenolytic enzyme. Proc Natl Acad Sci U S A 1965, 54:1197-1204.
42. Groth I., Grunewald N., Alban S. Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. Glycobiology 2009, 19:408-417.
43. Hadler-Olsen E., Fadnes B., Sylte I., Uhlin-Hansen L., Winberg J.O. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011, 278:28-45.
44. Haiko J., Suomalainen M., Ojala T., Lahteenmaki K., Korhonen T.K. Invited review: Breaking barriers--attack on innate immune defences by omptin surface proteases of enterobacterial pathogens. Innate Immun 2009, 15:67-80.
45. Hainard A., Tiberti N., Robin X., Ngoyi D.M., Matovu E., Enyaru J.C., Muller M., Turck N., Ndung'u J.M., Lejon V., Sanchez J.C. Matrix metalloproteinase-9 and intercellular adhesion molecule 1 are powerful staging markers for human African trypanosomiasis. Trop Med Int Health 2011, 16:119-126.
46. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996, 149:273-282.
47. Hishikawa K., Nakaki T., Fujii T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur J Pharmacol 2000, 392:19-22.
48. Huang H.Y. Medical treatment of endometriosis. Chang Gung Med J 2008, 31:431-440.
49. Iki K., Tsutsumi M., Kido A., Sakitani H., Takahama M., Yoshimoto M., Motoyama M., Tatsumi K., Tsunoda T., Konishi Y. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1999, 20:1323-1329.
50. Ip Y.C., Cheung S.T., Fan S.T. Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. Mol Carcinog 2007, 46:225-230.
51. Itoh Y., Ito N., Nagase H., Seiki M. The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface. J Biol Chem 2008, 283:13053-13062.
52. Jackson B.C., Nebert D.W., Vasiliou V. Update of human and mouse matrix metalloproteinase families. Hum Genomics 2010, 4:194-201.
53. Kang S., Zhao X.W., Wang N., Chen S.C., Zhou R.M., Li Y. Association of polymorphisms of the MMP-2 and TIMP-2 genes with the risk of endometriosis in North Chinese women. Fertil Steril 2008, 90:2023-2029.
54. Kessenbrock K, Brown M, Werb Z., (2011) Measuring matrix metalloproteinase activity in macrophages and polymorphonuclear leukocytes. Curr Protoc Immunol Chapter 14:Unit14.
55. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
56. Kim M.H., Kitson R.P., Albertsson P., Nannmark U., Basse P.H., Kuppen P.J., Hokland M.E., Goldfarb R.H. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J Immunol 2000, 164:5883-5889.
57. Kohrmann A., Kammerer U., Kapp M., Dietl J., Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009, 9:188.
58. Koyama Y., Naruo H., Yoshitomi Y., Munesue S., Kiyono S., Kusano Y., Hashimoto K., Yokoi T., Nakanishi H., Shimizu S., Okayama M., Oguri K. Matrix metalloproteinase-9 associated with heparan sulphate chains of GPI-anchored cell surface proteoglycans mediates motility of murine colon adenocarcinoma cells. J Biochem 2008, 143:581-592.
59. Kwan J.A., Schulze C.J., Wang W., Leon H., Sariahmetoglu M., Sung M., Sawicka J., Sims D.E., Sawicki G., Schulz R. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004, 18:690-692.
60. Lauer-Fields J.L., Chalmers M.J., Busby S.A., Minond D., Griffin P.R., Fields G.B. Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity. J Biol Chem 2009, 284:24017-24024.
61. Lauer-Fields J.L., Juska D., Fields G.B. Matrix metalloproteinases and collagen catabolism. Biopolymers 2002, 66:19-32.
62. Lauer-Fields J.L., Whitehead J.K., Li S., Hammer R.P., Brew K., Fields G.B. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem 2008, 283:20087-20095.
63. Li H., Nishio K., Yamashita K., Hayakawa T., Hoshino T. Cell cycle-dependent localization of tissue inhibitor of metalloproteinases-1 immunoreactivity in cultured human gingival fibroblasts. Nagoya J Med Sci 1995, 58:133-142.
64. Lim C.S., Shalhoub J., Gohel M.S., Shepherd A.C., Davies A.H. Matrix metalloproteinases in vascular disease--a potential therapeutic target?. Curr Vasc Pharmacol 2010, 8:75-85.
65. Liotta L.A., Rao C.N., Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986, 55:1037-1057.
66. Liotta L.A., Rao N.C., Terranova V.P., Barsky S., Thorgeirsson U. Tumor cell attachment and degradation of basement membranes. Symp Fundam Cancer Res 1983, 36:169-176.
67. Lopez-Otin C., Bond J.S. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008, 283:30433-30437.
68. Lopez-Otin C., Palavalli L.H., Samuels Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 2009, 8:3657-3662.
69. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006, 11:1696-1701.
70. Manicourt D.H., Fujimoto N., Obata K., Thonar E.J. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995, 38:1031-1039.
71. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?. Recent Pat Anticancer Drug Discov 2006, 1:91-103.
72. Mannello F. Matrix metalloproteinase polymorphisms and HIV anti-retroviral drugs: new implications of pharmacogenomics in therapeutic approaches. Pharmacogenomics J 2009, 9:355-357.
73. Mannello F. What does matrix metalloproteinase-1 expression in patients with breast cancer really tell us?. BMC Med 2011, 9:95.
74. Mannello F., Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001, 6:479-482.
75. Mannello F., Luchetti F., Falcieri E., Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005, 10:19-24.
76. Mannello F., Raffetto J.D. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res 2011, 3:149-158.
77. Mannello F., Tonti G., Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005, 5:285-298.
78. Mannello F., Tonti G.A. Statins and breast cancer: may matrix metalloproteinase be the missing link. Cancer Invest 2009, 27:466-470.
79. Mannello F., Tonti G.A., Bagnara G.P., Papa S. Role and function of matrix metalloproteinases in the differentiation and biological characterization of mesenchymal stem cells. Stem Cells 2006, 24:475-481.
80. Mannello F, Tonti GA, Papa S. (2005c) Are matrix metalloproteinases the missing link? pp 69-74.
81. Marchenko N.D., Marchenko G.N., Weinreb R.N., Lindsey J.D., Kyshtoobayeva A., Crawford H.C., Strongin A.Y. Beta-catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004, 36:942-956.
82. Martin M.D., Matrisian L.M. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007, 26:717-724.
83. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 2001, 13:534-540.
84. Minond D., Lauer-Fields J.L., Cudic M., Overall C.M., Pei D., Brew K., Moss M.L., Fields G.B. Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry 2007, 46:3724-3733.
85. Minond D., Lauer-Fields J.L., Nagase H., Fields G.B. Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry 2004, 43:11474-11481.
86. Monvoisin A., Bisson C., Si-Tayeb K., Balabaud C., Desmouliere A., Rosenbaum J. Involvement of matrix metalloproteinase type-3 in hepatocyte growth factor-induced invasion of human hepatocellular carcinoma cells. Int J Cancer 2002, 97:157-162.
87. Moor A.N., Vachon D.J., Gould L.J. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Repair Regen 2009, 17:832-839.
88. Morrison C.J., Butler G.S., Rodriguez D., Overall C.M. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol 2009, 21:645-653.
89. Murphy G., Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008, 29:290-308.
90. Murphy G., Nagase H. Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J 2011, 278:2-15.
91. Newby A.C. Do metalloproteinases destabilize vulnerable atherosclerotic plaques?. Curr Opin Lipidol 2006, 17:556-561.
92. Ogata R., Torimura T., Kin M., Ueno T., Tateishi Y., Kuromatsu R., Shimauchi Y., Sakamoto M., Tamaki S., Sata M., Tanikawa K. Increased expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinomas. Hum Pathol 1999, 30:443-450.
93. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van d V., Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001, 276:29596-29602.
94. Osteen K.G., Bruner K.L., Sharpe-Timms K.L. Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 1996, 14:247-255.
95. Osteen K.G., Keller N.R., Feltus F.A., Melner M.H. Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium. Gynecol Obstet Invest 1999, 48(Suppl 1):2-13.
96. Overall C.M. Matrix metalloproteinase substrate binding domains, modules and exosites. Overview and experimental strategies. Methods Mol Biol 2001, 151:79-120.
97. Overall C.M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002, 22:51-86.
98. Overall C.M., Butler G.S. Protease yoga: extreme flexibility of a matrix metalloproteinase. Structure 2007, 15:1159-1161.
99. Overall C.M., Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006, 94:941-946.
100. Oyarzun A., Arancibia R., Hidalgo R., Penafiel C., Caceres M., Gonzalez M.J., Martinez J., Smith P.C. Involvement of MT1-MMP and TIMP-2 in human periodontal disease. Oral Dis 2010, 16:388-395.
101. Papalambros E., Sigala F., Georgopoulos S., Menekakos C., Giatromanolaki A., Bastounis E., Sivridis E. Immunohistochemical expression of metalloproteinases MMP-2 and MMP-9 in abdominal aortic aneurysms: correlation with symptoms and aortic diameter. Int J Mol Med 2003, 12:965-968.
102. Papalambros E., Sigala F., Georgopoulos S., Panou N., Kavatzas N., Agapitos M., Bastounis E. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc Dis 2004, 18:160-165.
103. Papaspyridonos M., Smith A., Burnand K.G., Taylor P., Padayachee S., Suckling K.E., James C.H., Greaves D.R., Patel L. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2006, 26:1837-1844.
104. Pei P., Horan M.P., Hille R., Hemann C.F., Schwendeman S.P., Mallery S.R. Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention. Free Radic Biol Med 2006, 41:1315-1324.
105. Peng C.W., Liu X.L., Chen C., Liu X., Yang X.Q., Pang D.W., Zhu X.B., Li Y. Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials 2011, 32:2907-2917.
106. Pochetti G., Montanari R., Gege C., Chevrier C., Taveras A.G., Mazza F. Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8). J Med Chem 2009, 52:1040-1049.
107. Qiu F., Gao X.M., Luo G.L., Yang K.X., Wang H., Liu H., Wen Y. [Expression of matrix metalloproteinase and tissue inhibitor of metalloproteinase in adenomyosis]. Sichuan Da Xue Xue Bao Yi Xue Ban 2006, 37:118-122.
108. Quesada V., Ordonez G.R., Sanchez L.M., Puente X.S., Lopez-Otin C. The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res 2009, 37:D239-D243.
109. Raeber G.P., Lutolf M.P., Hubbell J.A. Mechanisms of 3-D migration and matrix remodeling of fibroblasts within artificial ECMs. Acta Biomater 2007, 3:615-629.
110. Ragino Y.I., Chernjavski A.M., Polonskaja Y.V., Tchimbal S.Y., Redjkin D.A., Semaeva E.V., Kashtanova E.V., Voevoda M.I. Blood levels of inflammatory and destructive biomarkers in coronary atherosclerosis of different severity. Bull Exp Biol Med 2010, 149:587-590.
111. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004, 6:96-102.
112. Ramon L., Gilabert-Estelles J., Castello R., Gilabert J., Espana F., Romeu A., Chirivella M., Aznar J., Estelles A. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay. Hum Reprod 2005, 20:272-278.
113. Reddy H.K., Tjahja I.E., Campbell S.E., Janicki J.S., Hayden M.R., Tyagi S.C. Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation. Mol Cell Biochem 2004, 264:183-191.
114. Rhee J.S., Coussens L.M. RECKing MMP function: implications for cancer development. Trends Cell Biol 2002, 12:209-211.
115. Ritter L.M., Garfield S.H., Thorgeirsson U.P. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem Biophys Res Commun 1999, 257:494-499.
116. Roderfeld M., Hemmann S., Roeb E. Mechanisms of fibrinolysis in chronic liver injury (with special emphasis on MMPs and TIMPs). Z Gastroenterol 2007, 45:25-33.
117. Rodriguez D., Morrison C.J., Overall C.M. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta 2010, 1803:39-54.
118. Rosenblum G., Meroueh S., Toth M., Fisher J.F., Fridman R., Mobashery S., Sagi I. Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc 2007, 129:13566-13574.
119. Rosenblum G., Van den Steen P.E., Cohen S.R., Grossmann J.G., Frenkel J., Sertchook R., Slack N., Strange R.W., Opdenakker G., Sagi I. Insights into the structure and domain flexibility of full-length pro-matrix metalloproteinase-9/gelatinase B. Structure 2007, 15:1227-1236.
120. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297.
121. Rybakowski J.K. Matrix Metalloproteinase-9 (MMP9)-A Mediating Enzyme in Cardiovascular Disease, Cancer, and Neuropsychiatric Disorders. Cardiovasc Psychiatry Neurol 2009, 2009:904836.
122. Saito N., Hatori T., Murata N., Zhang Z.A., Ishikawa F., Nonaka H., Iwabuchi S., Samejima H. A double three-step theory of brain metastasis in mice: the role of the pia mater and matrix metalloproteinases. Neuropathol Appl Neurobiol 2007, 33:288-298.
123. Schilling O., Overall C.M. Proteomic discovery of protease substrates. Curr Opin Chem Biol 2007, 11:36-45.
124. Schmitz J.P., Dean D.D., Schwartz Z., Cochran D.L., Grant G.M., Klebe R.J., Nakaya H., Boyan B.D. Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein; stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles. J Cell Biochem 1996, 61:375-391.
125. Schnaeker E.M., Ossig R., Ludwig T., Dreier R., Oberleithner H., Wilhelmi M., Schneider S.W. Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 2004, 64:8924-8931.
126. Seki M., Uzuki M., Ohmoto H., Yoshino K., Maeda S., Kokubun S., Sakurai M., Sawai T. [Matrix metalloproteinase (MMP-9) in patients with rheumatoid arthritis]. Ryumachi 1995, 35:792-801.
127. Seo D.W., Li H., Guedez L., Wingfield P.T., Diaz T., Salloum R., Wei B.Y., Stetler-Stevenson W.G. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114:171-180.
128. Sexton W.M., Lin Y., Kryscio R.J., Dawson D.R., Ebersole J.L., Miller C.S. Salivary biomarkers of periodontal disease in response to treatment. J Clin Periodontol 2011, 38:434-441.
129. Sharpe-Timms K.L., Cox K.E. Paracrine regulation of matrix metalloproteinase expression in endometriosis. Ann N Y Acad Sci 2002, 955:147-156.
130. Sheu B.C., Hsu S.M., Ho H.N., Lien H.C., Huang S.C., Lin R.H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001, 61:237-242.
131. Si-Tayeb K., Monvoisin A., Mazzocco C., Lepreux S., Decossas M., Cubel G., Taras D., Blanc J.F., Robinson D.R., Rosenbaum J. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 2006, 169:1390-1401.
132. Skarmoutsou E., D'Amico F., Marchini M., Stivala F., Malaponte G., Scorza R., Mazzarino M.C. Analysis of matrix metalloproteinase-9 gene polymorphism -1562C/T in patients suffering from systemic sclerosis with and without ulcers. Int J Mol Med 2011, 27:873-877.
133. Starckx S., Van den Steen P.E., Verbeek R., van Noort J.M., Opdenakker G. A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J Neuroimmunol 2003, 141:47-57.
134. Sterchi E.E. Special issue: metzincin metalloproteinases. Mol Aspects Med 2008, 29:255-257.
135. Sun X.F., Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer 2006, 5:43.
136. Tang Y., Kesavan P., Nakada M.T., Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2004, 2:73-80.
137. Tardif G., Reboul P., Pelletier J.P., Martel-Pelletier J. Ten years in the life of an enzyme: the story of the human MMP-13 (collagenase-3). Mod Rheumatol 2004, 14:197-204.
138. Tonti G.A., Mannello F., Cacci E., Biagioni S. Neural stem cells at the crossroads: MMPs may tell the way. Int J Dev Biol 2009, 53:1-17.
139. Troeberg L., Nagase H. Analysis of TIMP expression and activity. Methods Mol Med 2007, 135:251-267.
140. Ugalde A.P., Ordonez G.R., Quiros P.M., Puente X.S., Lopez-Otin C. Metalloproteases and the degradome. Methods Mol Biol 2010, 622:3-29.
141. van der Jagt M.F., Sweep F.C., Waas E.T., Hendriks T., Ruers T.J., Merry A.H., Wobbes T., Span P.N. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 2006, 237:289-297.
142. Van Kempen L.C., de Visser K.E., Coussens L.M. Inflammation, proteases and cancer. Eur J Cancer 2006, 42:728-734.
143. Vessillier S., Adams G., Chernajovsky Y. Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3. Protein Eng Des Sel 2004, 17:829-835.
144. Wagenaar-Miller R.A., Engelholm L.H., Gavard J., Yamada S.S., Gutkind J.S., Behrendt N., Bugge T.H., Holmbeck K. Complementary roles of intracellular and pericellular collagen degradation pathways in vivo. Mol Cell Biol 2007, 27:6309-6322.
145. Wallon U.M., Overall C.M. The hemopexin-like domain (C domain) of human gelatinase A (matrix metalloproteinase-2) requires Ca2+ for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components. J Biol Chem 1997, 272:7473-7481.
146. Worley J.R., Thompkins P.B., Lee M.H., Hutton M., Soloway P., Edwards D.R., Murphy G., Knauper V. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J 2003, 372:799-809.
147. Xi L., Du J., Li S., Li J., Liu H., Yao X. A combined molecular modeling study on gelatinases and their potent inhibitors. J Comput Chem 2010, 31:24-42.
148. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007, 211:19-26.
149. Yang Y., Candelario-Jalil E., Thompson J.F., Cuadrado E., Estrada E.Y., Rosell A., Montaner J., Rosenberg G.A. Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. J Neurochem 2010, 112:134-149.
150. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
151. Yu W.H., Woessner J.F. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7). J Biol Chem 2000, 275:4183-4191.
152. Zhang C., Kim S.K. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Mar Drugs 2009, 7:71-84.
153. Zhang Y., Lukacova V., Bartus V., Nie X., Sun G., Manivannan E., Ghorpade S.R., Jin X., Manyem S., Sibi M.P., Cook G.R., Balaz S. Binding of matrix metalloproteinase inhibitors to extracellular matrix: 3D-QSAR analysis. Chem Biol Drug Des 2008, 72:237-248.
154. Zhao W.Q., Li H., Yamashita K., Guo X.K., Hoshino T., Yoshida S., Shinya T., Hayakawa T. Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts. J Cell Sci 1998, 111(Pt 9):1147-1153.